Demographic overview
| HC | AQP4-IgG | MOG-IgG | |
| Subjects (N) | 75 | 197 | 32 |
| Number of eyes (N) | 148 | 317 | 55 |
| Age (years, mean±SD) | 32.3±9.6 | 41.8±12.1 | 36.5±13.7 |
| Sex (male, N (%)) | 25 (33.8) | 24 (12.2) | 10 (31.2) |
| EDSS (median (IQR)) | – | 3.5 (2.0–5.0) | 2.0 (1.5–2.5) |
| Average age at onset (years, median (IQR)) | – | 32.9 (24.9–42.4) | 30.0 (17.6–42.5) |
| Patients with a history of ON (N (%)) | – | 142 (72.1) | 24 (75.0) |
| Median number of ON episodes (median, IQR) | – | 1.00 (0.00–3.00) | 2.00 (1.00–4.00) |
| Disease duration (years, mean±SD) | – | 7.1±6.7 | 4.8±7.8 |
| Ethnicity (N (%)) | White (57 (761)) Asian (16 (21.3)) Hispanic (1 (1.3)) Other (1 (1.3)) | White (105 (53.3) Asian (56 (28.4)) African American (11 (5.6)) Other (25 (12.7)) | White (19 (59.4)) Asian (13 (40.6)) |
| Current treatment (N (%)) | Rituximab (51 (25.9)) Azathioprine (42 (21.3)) Mycophenolate Mofetil (31 (15.7)) Methotrexate (4 (2.0)) Other or missing (69 (35.0)) | Rituximab (6 (18.8)) Azathioprine (6 (18.8)) Prednisone (6 (18.8)) Mycophenolate mofetil (5 (15.6)) Other or missing (9 (28.1)) | |
| OCT device (N (%)) | Spectralis (75 (100)) | Spectralis (139 (70.6)) Cirrus (38 (19.3)) Topcon (20 (10.2)) | Spectralis (25 (78.1)) Cirrus (3 (9.4)) Topcon (4 (12.5)) |
Cirrus: Cirrus HD-OCT, Carl Zeiss Meditec Inc, Dublin, California, USA; Spectralis: SD-OCT, Heidelberg Engineering, Heidelberg, Germany;Topcon: Topcon 3D-OCT, Topcon Corp, Tokyo Japan.
AQP4-IgG, anti-aquaporin-4 antibody; EDSS, Expanded Disability Standard Scale; HCs, healthy controls; MOG-IgG, anti-myelin-oligodendrocyte-glycoprotein antibody; N, number of subjects; ON, optic neuritis.